KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Raw Materials: 2016-2024

Historic Raw Materials for Acadia Pharmaceuticals (ACAD) over the last 9 years, with Dec 2024 value amounting to $69.7 million.

  • Acadia Pharmaceuticals' Raw Materials rose 84.41% to $77.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.8 million, marking a year-over-year increase of 84.41%. This contributed to the annual value of $69.7 million for FY2024, which is 122.73% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Raw Materials stood at $69.7 million for FY2024, which was up 122.73% from $31.3 million recorded in FY2023.
  • In the past 5 years, Acadia Pharmaceuticals' Raw Materials ranged from a high of $69.7 million in FY2024 and a low of $1.9 million during FY2020.
  • In the last 3 years, Acadia Pharmaceuticals' Raw Materials had a median value of $31.3 million in 2023 and averaged $35.4 million.
  • Its Raw Materials has fluctuated over the past 5 years, first decreased by 16.25% in 2022, then skyrocketed by 501.34% in 2023.
  • Acadia Pharmaceuticals' Raw Materials (Yearly) stood at $1.9 million in 2020, then spiked by 233.89% to $6.2 million in 2021, then fell by 16.25% to $5.2 million in 2022, then soared by 501.34% to $31.3 million in 2023, then spiked by 122.73% to $69.7 million in 2024.